YIH
MAZE

Y-Intercept (HK)’s Maze Therapeutics MAZE Stock Holding History

Y-Intercept (HK)’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Sell
14,370
-7,358
-34% -$193K 0.01% 1357
2026
Q1 		$649K Buy
+21,728
New +$959K 0.01% 1195

Other funds holding MAZE

FWP
Falcon Wealth Planning Ontario, California $1.58B AUM 20.99% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Y-Intercept (HK)'s MAZE Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Maze Therapeutics (MAZE) stake by 34% in Q2 2026, selling an estimated $193K and leaving 14,370 shares worth $429K. The position accounts for 0.01% of the portfolio, ranked #1357.

Y-Intercept (HK) first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. The position peaked at $649K in Q1 2026. 9 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Y-Intercept (HK) held 14,370 shares of Maze Therapeutics worth $429K as of Q2 2026.
  • Y-Intercept (HK) sold 7,358 Maze Therapeutics shares in Q2 2026, an estimated $193K.
  • Maze Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1357 holding.
  • Y-Intercept (HK) first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Y-Intercept (HK)'s Maze Therapeutics position peaked at $649K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.